{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,17]],"date-time":"2026-08-17T14:30:21Z","timestamp":1786977021415,"version":"build-2736575974"},"reference-count":38,"publisher":"Wiley","issue":"3","license":[{"start":{"date-parts":[[2016,2,24]],"date-time":"2016-02-24T00:00:00Z","timestamp":1456272000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"funder":[{"name":"NIH","award":["U54-GM-104940"],"award-info":[{"award-number":["U54-GM-104940"]}]},{"name":"NIH","award":["P306-M-206392-01A1"],"award-info":[{"award-number":["P306-M-206392-01A1"]}]},{"name":"NIH","award":["K23-HL-093387"],"award-info":[{"award-number":["K23-HL-093387"]}]},{"DOI":"10.13039\/100002291","name":"Pulmonary Hypertension Association","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100002291","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100001844","name":"Scleroderma Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100001844","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Sibley Hospital Foundation"},{"name":"Actelion"},{"DOI":"10.13039\/100005564","name":"Gilead","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100005564","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Arthritis &amp; Rheumatology"],"published-print":{"date-parts":[[2016,3]]},"abstract":"<jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To compare time to clinical worsening (TTCW) based on initial oral therapy for pulmonary arterial hypertension (PAH) in patients with systemic sclerosis (SSc)\u2013related PAH.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Using data from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) registry (a multicenter prospective observational study enrolling SSc patients with incident pulmonary hypertension), we selected patients with group 1 PAH (World Health Organization Clinical Classification system) who received initial therapy (for 6 months) with an endothelin receptor antagonist (ERA), a phosphodiesterase 5 (PDE5) inhibitor, or a combination of these 2 agents (ERA\/PDE5 inhibitor). The main outcome was TTCW, defined as the first occurrence of death, PAH\u2010related hospitalization, lung transplantation, initiation of parenteral prostacyclin treatment, or worsening symptoms.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Ninety\u2010eight patients (24 in the ERA group, 59 in the PDE5 inhibitor group, and 15 in the ERA\/PDE5 inhibitor group) were included. No significant differences in the baseline characteristics of the patients were observed. TTCW was significantly worse in patients in the ERA group compared with those in the PDE5 inhibitor group or the ERA\/PDE5 inhibitor group. Ten patients (41.6%) in the ERA group died during the 3\u2010year observation period, compared with 4 patients (6.8%) in the PDE5 inhibitor group and 1 patient (6.7%) in the ERA\/PDE5 inhibitor group. Baseline factors that were independently associated with a shorter TTCW were initial treatment with an ERA (hazard ratio [HR] 2.63 [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.009]), lower diffusing capacity for carbon monoxide (HR 0.69 per 10% of predicted change [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.04]), and higher pulmonary vascular resistance (HR 1.10 per Wood unit change [\n                      <jats:italic>P<\/jats:italic>\n                      \u2009=\u20090.007]).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Compared with initial treatment with a PDE5 inhibitor or combination therapy with an ERA and a PDE5 inhibitor, initial therapy with an ERA in patients with SSc\u2010related PAH was associated with significantly worse TTCW, even after adjustment for commonly accepted prognostic factors. Further study into the optimal initial oral therapy for patients with SSc\u2010related PAH is needed.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1002\/art.39478","type":"journal-article","created":{"date-parts":[[2015,10,19]],"date-time":"2015-10-19T10:48:44Z","timestamp":1445251724000},"page":"740-748","source":"Crossref","is-referenced-by-count":25,"title":["Association Between Initial Oral Therapy and Outcomes in Systemic Sclerosis\u2013Related Pulmonary Arterial Hypertension"],"prefix":"10.1002","volume":"68","author":[{"given":"Matthew R.","family":"Lammi","sequence":"first","affiliation":[{"name":"Louisiana State University Health Sciences Center New Orleans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Stephen C.","family":"Mathai","sequence":"additional","affiliation":[{"name":"Johns Hopkins University Baltimore Maryland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley Ann","family":"Saketkoo","sequence":"additional","affiliation":[{"name":"Tulane University School of Medicine New Orleans Louisiana"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robyn T.","family":"Domsic","sequence":"additional","affiliation":[{"name":"University of Pittsburgh Pittsburgh Pennsylvania"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Bojanowski","sequence":"additional","affiliation":[{"name":"Louisiana State University Health Sciences Center New Orleans"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Daniel E.","family":"Furst","sequence":"additional","affiliation":[{"name":"University of California Los Angeles"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia D.","family":"Steen","sequence":"additional","affiliation":[{"name":"Georgetown University School of Medicine Washington DC"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"name":"for the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma Investigators","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2016,2,24]]},"reference":[{"key":"e_1_2_6_2_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.12-2396"},{"key":"e_1_2_6_3_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2006.066068"},{"key":"e_1_2_6_4_1","doi-asserted-by":"publisher","DOI":"10.1002\/art.22069"},{"key":"e_1_2_6_5_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.077149"},{"key":"e_1_2_6_6_1","doi-asserted-by":"publisher","DOI":"10.1093\/eurheartj\/ehp022"},{"key":"e_1_2_6_7_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.029"},{"key":"e_1_2_6_8_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2005.048967"},{"key":"e_1_2_6_9_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1213917"},{"key":"e_1_2_6_10_1","first-page":"2417","article-title":"Sildenafil for pulmonary arterial hypertension associated with connective tissue disease","volume":"34","author":"Badesch DB","year":"2007","journal-title":"J Rheumatol"},{"key":"e_1_2_6_11_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.108.839274"},{"key":"e_1_2_6_12_1","doi-asserted-by":"publisher","DOI":"10.1136\/ard.2007.069609"},{"key":"e_1_2_6_13_1","doi-asserted-by":"publisher","DOI":"10.3899\/jrheum.101243"},{"key":"e_1_2_6_14_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2013.10.032"},{"key":"e_1_2_6_15_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCOUTCOMES.110.957951"},{"key":"e_1_2_6_16_1","volume-title":"Systemic sclerosis","author":"Medsger T.","year":"2004"},{"key":"e_1_2_6_17_1","first-page":"253","volume-title":"Nomenclature and Criteria for Diagnosis of Diseases of the Heart and Great Vessels","author":"The Criteria Committee of the New York Heart Association","year":"1994"},{"key":"e_1_2_6_18_1","doi-asserted-by":"publisher","DOI":"10.1111\/1467-9876.00155"},{"key":"e_1_2_6_19_1","volume-title":"Multivariate data analysis","author":"Hair JF","year":"1995"},{"key":"e_1_2_6_20_1","first-page":"S738","article-title":"Initial therapy with an endothelin receptor antagonist is associated with worse outcomes in patients with systemic sclerosis and pulmonary arterial hypertension: observations from the Pulmonary Hypertension Assessment and Recognition of Outcomes in Scleroderma (PHAROS) cohort [abstract]","volume":"66","author":"Lammi MR","year":"2014","journal-title":"Arthritis Rheumatol"},{"key":"e_1_2_6_21_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.911818"},{"key":"e_1_2_6_22_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.109.898122"},{"key":"e_1_2_6_23_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200912-1820OC"},{"key":"e_1_2_6_24_1","doi-asserted-by":"publisher","DOI":"10.1378\/chest.10-0260"},{"key":"e_1_2_6_25_1","doi-asserted-by":"publisher","DOI":"10.1002\/acr.22121"},{"key":"e_1_2_6_26_1","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1413687"},{"key":"e_1_2_6_27_1","doi-asserted-by":"publisher","DOI":"10.1146\/annurev.pharmtox.41.1.851"},{"key":"e_1_2_6_28_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0163-7258(02)00235-8"},{"key":"e_1_2_6_29_1","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1042\/cs1040143","article-title":"ETA receptors mediate vasoconstriction, whereas ETB receptors clear endothelin\u20101 in the splanchnic and renal circulation of healthy men","volume":"104","author":"Bohm F","year":"2003","journal-title":"Clin Sci (Lond)"},{"key":"e_1_2_6_30_1","doi-asserted-by":"publisher","DOI":"10.1124\/jpet.108.142976"},{"key":"e_1_2_6_31_1","doi-asserted-by":"publisher","DOI":"10.1016\/S0140-6736(08)60919-8"},{"key":"e_1_2_6_32_1","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.107.742510"},{"key":"e_1_2_6_33_1","doi-asserted-by":"publisher","DOI":"10.1016\/j.jacc.2009.07.033"},{"key":"e_1_2_6_34_1","doi-asserted-by":"publisher","DOI":"10.1038\/nm1175"},{"key":"e_1_2_6_35_1","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200410-1411OC"},{"key":"e_1_2_6_36_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.89.4.1733"},{"key":"e_1_2_6_37_1","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00070209"},{"key":"e_1_2_6_38_1","doi-asserted-by":"publisher","DOI":"10.1161\/01.CIR.0000084544.54513.E2"},{"key":"e_1_2_6_39_1","doi-asserted-by":"publisher","DOI":"10.7326\/0003-4819-115-5-343"}],"container-title":["Arthritis &amp; Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1002%2Fart.39478","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/pdf\/10.1002\/art.39478","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,8]],"date-time":"2025-10-08T17:52:33Z","timestamp":1759945953000},"score":1,"resource":{"primary":{"URL":"https:\/\/acrjournals.onlinelibrary.wiley.com\/doi\/10.1002\/art.39478"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,2,24]]},"references-count":38,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2016,3]]}},"alternative-id":["10.1002\/art.39478"],"URL":"https:\/\/doi.org\/10.1002\/art.39478","archive":["Portico"],"relation":{},"ISSN":["2326-5191","2326-5205"],"issn-type":[{"value":"2326-5191","type":"print"},{"value":"2326-5205","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,2,24]]}}}